Medical therapy for asthma: Updates from the NAEPP guidelines

American Family Physician

Volumn 82, Issue 10, 2010, Pages 1242-1251

  Elward, Kurtis S ^a,b   Pollart, Susan M ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL FUMARATE; IPRATROPIUM BROMIDE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LEVALBUTEROL; MONTELUKAST; NEDOCROMIL; OMALIZUMAB; PIRBUTEROL ACETATE; SALBUTAMOL; SALMETEROL XINAFOATE; THEOPHYLLINE; ZAFIRLUKAST; ANTIASTHMATIC AGENT;

ADD ON THERAPY; ANAPHYLAXIS; ANXIETY; ARTICLE; ASTHMA; DISEASE CONTROL; DISEASE EXACERBATION; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPHONIA; HEART PALPITATION; HUMAN; LOW DRUG DOSE; MILD PERSISTENT ASTHMA; MODERATE PERSISTENT ASTHMA; OUTCOME ASSESSMENT; PATIENT CARE; PRACTICE GUIDELINE; SEVERE PERSISTENT ASTHMA; SIDE EFFECT; TACHYCARDIA; TACHYPHYLAXIS; TOTAL QUALITY MANAGEMENT; TREATMENT PLANNING; TREMOR; REVIEW; TREATMENT OUTCOME;

ANTI-ASTHMATIC AGENTS; ASTHMA; HUMANS; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

EID: 79952116401     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Popa V. Emergency department visits in asthma: should all be prevented? Chest. 2001;120(4):1058-1061.
2. Weiss KB, Gergen PJ, Hodgson TA. An economic evaluation of asthma in the United States. N Engl J Med. 1992;326(13):862-866.
3. Centers for Disease Control and Prevention. National surveillance for asthma-United States, 1980-2004. MMWR Morb Mortal Wkly Rep. 2007;56(SS-8):43.
4. Dales RE, Schweitzer I, Kerr P, Gougeon L, Rivington R, Draper J. Risk factors for recurrent emergency department visits for asthma. Thorax. 1995;50(5):520-524.
5. Akinbami L. Office of Analysis and Epidemiology, Centers for Disease Control and Prevention. Asthma prevalence, health care use and mortality: United States, 2003-05. November 2006. http://www.cdc.gov/nchs/data/hestat/asthma03-05/asthma03-05.htm. Accessed April 1, 2009.
6. Fredrickson DD, et al. Understanding frequent emergency room use by Medicaid-insured children with asthma: a combined quantitative and qualitative study. J Am Board Fam Pract. 2004;17(2):96-100.
7. National Heart, Lung, and Blood Institute, National Asthma Education and Prevention Program. Expert panel report 3: guidelines for the diagnosis and management of asthma. Bethesda, Md.: National Heart, Lung, and Blood Institute; Revised August 2007. NIH publication no. 07-4051. http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf. Accessed May 10, 2009.
8. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM; SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol [published correction appears in Chest. 2006;129(5):1393]. Chest. 2006;129(1):15-26.
9. The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med. 2000;343(15):1054-1063.
10. Lipworth BJ, Sims EJ, Das SK, Morice AH, O'Connor BJ. Bronchoprotection with formoterol via dry powder and metered-dose inhalers in patients with asthma. Ann Allergy Asthma Immunol. 2005;95(3):283-290.
11. Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone: a cross-over study in healthy volunteers. Chest. 2002;122(2):510-516.
12. Dolovich MB, Ahrens RC, Hess DR, et al.; American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest. 2005;127(1):335-371.
13. Leung DY, Bloom JW. Update on glucocorticoid action and resistance. J Allergy Clin Immunol. 2003;111(1):3-22.
14. Chalmers GW, Macleod KJ, Little SA, Thomson LJ, McSharry CP, Thomson NC. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax. 2002;57(3):226-230.
15. Chaudhuri R, Livingston E, McMahon AD, Thomson L, Borland W, Thomson NC. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am J Respir Crit Care Med. 2003;168(11):1308-1311.
16. Chan MT, Leung DY, Szefler SJ, Spahn JD. Difficult-to-control asthma: clinical characteristics of steroid-insensitive asthma. J Allergy Clin Immunol. 1998;101(5):594-601.
17. Federico MJ, Covar RA, Brown EE, Leung DY, Spahn JD. Racial differences in T-lymphocyte response to glucocorticoids. Chest. 2005;127(2):571-578.
18. DelGaudio JM. Steroid inhaler laryngitis: dysphonia caused by inhaled fluticasone therapy. Arch Otolaryngol Head Neck Surg. 2002;128(6):677-681.
19. O'Driscoll BR, Kalra S, Wilson M, Pickering CA, Carroll KB, Woodcock AA. Double-blind trial of steroid tapering in acute asthma. Lancet. 1993;341(8841):324-327.
20. Ostrom NK, Decotiis BA, Lincourt WR, et al. Comparative efficacy and safety of low-dose fluticasone propionate and montelukast in children with persistent asthma. J Pediatr. 2005;147(2):213-220.
21. Peters SP, Anthonisen N, Castro M, et al.; American Lung Association Asthma Clinical Research Centers. Randomized comparison of strategies for reducing treatment in mild persistent asthma [published correction appears in N Engl J Med. 2007;357(7):728]. N Engl J Med. 2007;356(20):2027-2039.
22. Dahlén SE, Malmström K, Nizankowska E, et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165(1):9-14.
23. Pearlman DS, Chervinsky P, LaForce C, et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med. 1992;327(20):1420-1425.
24. Nelson JA, Strauss L, Skowronski M, Ciufo R, Novak R, McFadden ER Jr. Effect of long-term salmeterol treatment on exercise-induced asthma. N Engl J Med. 1998;339(3):141-146.
25. Simons FE, Gerstner TV, Cheang MS. Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment. Pediatrics. 1997;99(5):655-659.
26. Smyth ET, Pavord ID, Wong CS, Wisniewski AF, Williams J, Tattersfield AE. Interaction and dose equivalence of salbutamol and salmeterol in patients with asthma. BMJ. 1993;306(6877):543-545.
27. Wechsler ME, Lehman E, Lazarus SC, et al.; National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. Beta-adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med. 2006;173(5):519-526.
28. Bleecker ER, Postma DS, Lawrance RM, Meyers DA, Ambrose HJ, Goldman M. Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet. 2007;370(9605):2118-2125.
29. Bailey W, Castro M, Matz J, et al. Asthma exacerbations in African Americans treated for 1 year with combination fluticasone propionate and salmeterol or fluticasone propionate alone. Curr Med Res Opin. 2008;24(6):1669-1682.
30. Solèr M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics [published correction appears in Eur Respir J. 2001;18(4):739-740]. Eur Respir J. 2001;18(2):254-261.
31. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108(2):184-190.
32. Xolair. Drugs. com. http://www.drugs.com/xolair.html. Accessed August 18, 2010.
33. Red Book. Montvale, N.J.: Medical Economics Data; 2010.
34. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med. 1996;153(5):1481-1488.
35. Pauwels RA, Löfdahl CG, Postma DS, et al.; Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. Effect of inhaled formoterol and budesonide on exacerbations of asthma [published correction appears in N Engl J Med. 1998;338(2):139]. N Engl J Med. 1997;337(20):1405-1411.
36. Papi A, Canonica GW, Maestrelli P, et al.; BEST Study Group. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med. 2007;356(20):2040-2052.
37. Nelson HS. Beta-adrenergic bronchodilators. N Engl J Med. 1995;333(8):499-506.
38. Lipworth BJ, Struthers AD, McDevitt DG. Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics. Am Rev Respir Dis. 1989;140(3):586-592.
39. Repsher LH, Anderson JA, Bush RK, et al. Assessment of tachyphylaxis following prolonged therapy of asthma with inhaled albuterol aerosol. Chest. 1984;85(1):34-38.
40. Lawford P, McKenzie D. Pressurized aerosol inhaler technique: how important are inhalation from residual volume, inspiratory flow rate and the time interval between puffs? Br J Dis Chest. 1983;77(3):276-281.
41. Doshan HD, Rosenthal RR, Brown R, Slutsky A, Applin WJ, Caruso FS. Celiprolol, atenolol and propranolol: a comparison of pulmonary effects in asthmatic patients. J Cardiovasc Pharmacol. 1986;8(suppl 4):S105-S108.
42. Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med. 2002;137(9):715-725.
43. Levalbuterol. Drugs. com. http://www.drugs.com. Accessed September 9, 2010.
44. Albuterol. Drugs. com. http://www.drugs.com. Accessed September 9, 2010.
45. Hendeles L, Colice GL, Meyer RJ. Withdrawal of albuterol inhalers containing chlorofluorocarbon propellants. N Engl J Med. 2007;356(13):1344-1351.
46. Ramsdell JW, Colice GL, Ekholm BP, Klinger NM. Cumulative dose response study comparing HFA-134a albuterol sulfate and conventional CFC albuterol in patients with asthma. Ann Allergy Asthma Immunol. 1998;81(6):593-599.
47. Newman SP. Spacer devices for metered dose inhalers. Clin Pharmacokinet. 2004;43(6):349-360.
48. Cates CJ, Crilly JA, Rowe BH. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev. 2006;(2):CD000052.
49. Nathan RA. Beta 2 agonist therapy: oral versus inhaled delivery. J Asthma. 1992;29(1):49-54.
50. Rebuck AS, Chapman KR, Abboud R, et al. Nebulized anticholinergic and sympathomimetic treatment of asthma and chronic obstructive airways disease in the emergency room. Am J Med. 1987;82(1):59-64.
51. Ducharme FM, Davis GM. Randomized controlled trial of ipratropium bromide and frequent low doses of salbutamol in the management of mild and moderate acute pediatric asthma. J Pediatr. 1998;133(4):479-485.
52. Gibson PG, Powell H, Coughlan J, et al. Self-management education and regular practitioner review for adults with asthma. Cochrane Database Syst Rev. 2003;(1):CD001117.
53. Gibson PG, Powell H. Written action plans for asthma: an evidence-based review of the key components. Thorax. 2004;59(2):94-99.
54. Bhogal S, Zemek R, Ducharme FM. Written action plans for asthma in children. Cochrane Database Syst Rev. 2006;(3):CD005306.
55. Regional Asthma Management and Prevention, a program of the Public Health Institute. http://www.rampasthma.org/. Accessed September 23, 2010.